SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Report abuse about a comment

Project should include participation by supply chain partners

Counterfeiting is a priority across the phamaceutical supply chain. Serialization and Pedigree requirements and solutions are still evolving. I would like to see participation in these types of projects by Manufacturers, Distributors, Retailers and Consumers. Also, the many standards determining bodies, i.e, GS1, HDMA, etc. should be connected to the effort. There needs to be a holistic approach that ties together the many requirements and regulations into one universal solution with defined standards. Many supply chain partners are looking to 2015 and the California mandate. This effort should be synergistic with state and federal regulations.

Posted by Bill Ricigliano
14 October 2010 | 14h31

Please fill in the box below to tell us why you feel the post breaks our rules. When you are finished, click on "Send" so that it can be reviewed by a moderator.

Your name *
Your email *

We will not publish your email on the site

Reason *

Back to: FDA & WHO collaborate on surveillance of counterfeit drugs

Spotlight

Third time's a charm: Pfizer to buy Hospira for $17bn
breaking news

Third time's a charm: Pfizer to buy Hospira for $17bn

Pfizer has entered into a definitive merger agreement to buy Hospira for $17bn.

Vertellus buys antiretroviral API reagent plant from Dow

Vertellus buys antiretroviral API reagent plant from Dow

Specialty chemicals firm Vertellus will continue to supply antiretroviral drugmakers sodium borohydride following its takeover of a...

ScinoPharm: profits fall on higher costs, an idle plant and lower Qsymia sales

ScinoPharm: profits fall on higher costs, an idle plant and lower Qsymia sales

ScinoPharm was hurt by weak US demand for the weight loss pill Qsymia, higher raw material prices...

Analyst: Pfizer's withdrawal from Repligen deal "not smart" amid growing Big Pharma interest in SMA

Analyst: Pfizer's withdrawal from Repligen deal "not smart" amid growing Big Pharma interest in SMA

Pfizer must act fast to convince investors it can compete with Roche and Biogen Idec for a...

MUGAS-funded Tamiflu analysis included fewer studies than Cochrane review

MUGAS-funded Tamiflu analysis included fewer studies than Cochrane review

Researchers claiming Tamiflu cuts flu symptom duration and hospitalisations analysed less than half as many studies as...